Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity Feb 6, 2020 08:00AM
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity Feb 7, 2019 04:00PM
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity Nov 7, 2018 08:00AM
Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity Aug 2, 2018 08:00AM
Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity May 3, 2018 04:00PM
View Older Stories

Mar 14, 2018 07:00AM Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
Mar 12, 2018 07:00AM Alnylam Retains Global Rights to Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Feb 8, 2018 08:00AM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
Jan 25, 2018 04:01PM Alnylam Pharma (ALNY) Announces EMA Acceptance of MAA for Patisiran for hATTR Amyloidosis
Jan 25, 2018 04:00PM Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Jan 8, 2018 05:55AM Alnylam Pharma (ALNY) Releases Corporate Goals for 2018
Jan 8, 2018 05:53AM Alnylam Pharma (ALNY) and Sanofi (SNY) Report Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Jan 7, 2018 03:30PM Alnylam Announces 2018 Corporate Goals
Jan 7, 2018 03:01PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Jan 7, 2018 03:00PM Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance
Jan 7, 2018 03:00PM Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Dec 18, 2017 07:04AM Sanofi (SNY) and Alnylam (ALNY) Submit EU Marketing Authorization Application for Patisiran to Treat hATTR amyloidosis
Dec 18, 2017 07:04AM Alnylam Pharma (ALNY) & Sanofi (SNY) Announce Marketing Authorisation Application to EMA for Patisiran for Treatment of Hereditary ATTR Amyloidosis
Dec 18, 2017 07:01AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 18, 2017 07:00AM Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
Dec 18, 2017 07:00AM Alnylam and Sanofi Submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Dec 15, 2017 09:28AM Pre-Open Movers 12/15: (DDR) (ALNY) (HES) Higher; (TROV) (VSTM) (CSX) Lower (more...)
Dec 15, 2017 07:03AM Alnylam Pharma (ALNY) and Sanofi Genzyme (SNY) Reports Lift of FDA Hold on Fitusiran
Dec 15, 2017 07:03AM Sanofi (SNY) and Alnylam (ALNY) Announce FDA Lifted Clinical hold on Fitusiran
Dec 15, 2017 07:01AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 15, 2017 07:00AM Sanofi: FDA lifts clinical hold on fitusiran
Dec 15, 2017 07:00AM FDA Lifts Clinical Hold on Fitusiran
Dec 12, 2017 07:10AM Alnylam Pharma (ALNY) Completes Submission of NDA to FDA for Patisiran for Treatment of Hereditary ATTR (hATTR) Amyloidosis
Dec 12, 2017 07:00AM Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Dec 11, 2017 07:05AM Alnylam Pharma (ALNY) Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of ATTR Amyloidosis
Dec 11, 2017 07:00AM Alnylam Announces Expansion of U.S. Orphan Drug Designation for Patisiran to Treatment of Transthyretin-Mediated Amyloidosis
Nov 20, 2017 07:01AM Alnylam Pharma (ALNY) Granted FDA Breakthrough Therapy Designation for Patisiran
Nov 20, 2017 07:00AM U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
Nov 16, 2017 07:08AM Alnylam Pharma (ALNY) Commences Rolling Submission of New Drug Application FDA for Patisiran
Nov 16, 2017 07:00AM Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Nov 13, 2017 07:33AM Alnylam Pharma (ALNY) Granted Accelerated Assessment of Patisiran by EMA
Nov 13, 2017 07:30AM European Medicines Agency (EMA) Grants Alnylam Accelerated Assessment of Patisiran for Patients with Hereditary ATTR (hATTR) Amyloidosis
Nov 9, 2017 04:00PM Alnylam Pharma (ALNY) Announces Successful Outcome Following FDA Type A Meeting on Fitusiran Program
Nov 9, 2017 04:00PM Alnylam Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia
Nov 7, 2017 04:00PM Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity
Nov 3, 2017 11:00AM Alnylam Reports Positive Preliminary Results from Ongoing Phase 1/2 Study of Lumasiran (ALN-GO1) in Patients with Primary Hyperoxaluria Type 1 (PH1)
Nov 2, 2017 10:46AM Alnylam Pharma (ALNY), Sanofi (SNY) Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in hATTR Amyloidosis Patients with Polyneuropathy
Nov 2, 2017 10:46AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Nov 2, 2017 10:45AM Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
Nov 2, 2017 10:45AM Alnylam and Sanofi Present Positive Complete Results from APOLLO Phase 3 Study of Investigational Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 10:12AM Arbutus Biopharma (ABUS) Gains Sharply Following Alnylam Trial Success
Sep 20, 2017 07:36AM Ionis Pharma (IONS) Sinks on Alnylam (ALNY) Patisiran Success
Sep 20, 2017 07:02AM Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
Sep 20, 2017 07:01AM Sanofi (SNY) and Alnylam (ALNY) APOLLO Phase 3 Study of Patisiran in hATTR Meets Primary, Secondary Endpoints
Sep 20, 2017 07:00AM Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 07:00AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 20, 2017 06:58AM Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Sep 7, 2017 07:02AM Alnylam Pharma (ALNY) Reports Fatal Thrombotic Event in Study of Fitusiran, Suspends Dosing
Sep 7, 2017 07:00AM Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs
Aug 9, 2017 04:00PM Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Period Activity
View Older Stories